Physician

Xiaowen Wang, MD

According to 2025 Medicare claims, Xiaowen Wang, MD (NPI: 1548371180) practices medical oncology in the Everett, WA market, with the plurality of this provider's patient population coming from Snohomish, WA. This provider's primary affiliated billing organization is OPTUM CARE WASHINGTON PLLC (NPI: 1831186766; TIN: 910214500) and primary practice location at 98201-1621. Wang is affiliated with the PSW ACO (ACO ID: A5323) and CareMount Value Partners IPA (ACO ID: D0019), participating under both the MSSP and REACH models.

Wang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 498 traditional Medicare patients, billed 75,040 HCPCS/CPT codes, and received $1,538,975 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,457 prescription claims across 363 beneficiaries totaling $4,699,072 in drug costs, led by Kisqali (Ribociclib Succinate). DME data shows 15 claims. Open Payments data shows 35 records totaling $68,524. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $679,124 to $1,538,975. Similarly, Part D prescription costs have risen steadily, from $1,338,479 to $4,699,072. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $2,493 to $3,277.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	404	41,875	$679,124
2016	382	70,454	$756,614
2017	427	43,434	$788,966
2018	421	42,607	$745,037
2019	482	65,522	$1,213,840
2020	387	49,443	$929,500
2021	425	61,198	$1,165,659
2022	417	74,488	$1,460,303
2023	416	80,721	$1,317,969
2024	498	75,040	$1,538,975

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	202	1,128	$1,338,479
2016	228	1,203	$1,459,119
2017	225	1,002	$1,481,754
2018	240	1,081	$1,636,207
2019	260	1,199	$2,028,936
2020	273	1,252	$2,406,627
2021	243	1,055	$1,830,367
2022	258	964	$1,200,993
2023	287	1,116	$2,518,429
2024	363	1,457	$4,699,072

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	57	$1,470
2016	N/R	142	$5,880
2017	N/R	90	$7,953
2018	N/R	144	$11,190
2019	N/R	170	$9,850
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	45	$1,523
2024	N/R	15	$188

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	126	203	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	148	188	$88
80053	Blood test, comprehensive group of blood chemicals	136	357	$10
36415	Insertion of needle into vein for collection of blood sample	154	397	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	130	423	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kisqali	Ribociclib Succinate	36	1,008	$672,622
Imbruvica	Ibrutinib	19	538	$593,286
Ibrance	Palbociclib	34	952	$560,016
Jakafi	Ruxolitinib Phosphate	18	840	$460,512
Lenalidomide	Lenalidomide	25	686	$391,893

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	15	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$5,524	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	21	$63,000	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Xiaowen Wang, MD?

Tedicare shows public-source Medicare data for Xiaowen Wang, MD (NPI 1548371180), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Xiaowen Wang, MD have ACO affiliation data?

Xiaowen Wang, MD is shown with ACO affiliation data for PSW ACO (MSSP, ACO ID A5323) and CareMount Value Partners IPA (REACH, ACO ID D0019).

What billing organization is linked to Xiaowen Wang, MD?

Xiaowen Wang, MD is linked to OPTUM CARE WASHINGTON PLLC (billing NPI 1831186766) in the available physician profile data.

Does Xiaowen Wang, MD have Open Payments data?

Xiaowen Wang, MD has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.